Adeno-Associated Virus (AAV) Versus Immune Response
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood–brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of adeno-associated virus (AAV) serotypes, antibody epitopes, and ways to modify antibody-binding sites. AAVs capsid has also been engineered to re-direct tissue tropism, reduce ubiquitination, and promote passage across the BBB. Furthermore, the use of high(er) dose recombinant AAV (rAAV) has been accompanied by a better understanding of immune responses in both experimental animals and early clinical trials, and novel work is being performed to modulate the immune response. While the immune responses to rAAV remains a major challenge in translating experimental drugs to approved medicine, and will likely require more than a single solution, we now better understand the hurdles to formulate and test experimental solutions to surmount them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Endosomal TLR9, present in Kupffer cells or DCs, particularly binds to unmethylated CpG dinucleotides in the double-stranded DNA (dsDNA) vector genomes [36].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“With the exception of TLR3, all other mammalian TLRs signal through the signaling adaptor myeloid differentiation primary response gene 88 (MyD88), and this cascade leads to phosphorylation and degradation of Inhibitor of NF kappa B (IκB), thereby releasing inhibition on NF-κB and allowing it to translocate to the nuc…”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“Subsequently, it was determined to be an AAV capsid-specific CD8+ cytotoxic T cell response that likely led to the decline of factor IX expression, while other patients had preexisting humoral antibodies [22].”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“When tested against two IVIG neutralization preparations, AAV-LK03 demonstrated significant levels of resistance, which is somewhat surprising considering the amount of cross-reactivity between AAV serotypes in the human population [21], and AAV2 and AAV3b in particular [20].”
BackgroundDNA shuffling of a family of genes from diverse species accelerates directed evolution
Crameri, A., Raillard, S.-A., Bermudez, E., & Stemmer, W. P. C. (1998) · Nature · doi:10.1038/34663 · Cited by 825 · cited 5×
“Coupling this reassembly with error prone PCR further increased the diversity of resulting chimeric capsids.”
BackgroundInfluentialFriedmann, T., & Roblin, R. (1972) · Science · doi:10.1126/science.175.4025.949 · Cited by 815 · cited 1×
“Friedmann and Roblin postulated several barriers to gene therapy decade ago [1].”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“However, natural infection studies demonstrated existing wt AAV in human samples, and the presence of neutralizing antibodies in healthy subjects throughout the world [18,19] or in specific gene therapy target populations [20].”
BackgroundMapping of the Inducible IκB Phosphorylation Sites That Signal Its Ubiquitination and Degradation†
Didonato, J., Mercurio, F., Rosette, C., Wu-Li, J., Suyang, H., Ghosh, S., & Karin, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1295 · Cited by 707 · cited 1×
“In the case of I Kappa B degradation, serine phosphorylation is the key modification leading to ubiquitination [41].”
BackgroundGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Cited by
Items 101–122 of 122
Therapeutic Window for the Treatment of Lafora Disease
Varea, O., Guinovart, J. J., & Durán, J. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0053 · Cited by 2
Specific detection of duck adeno-associated virus using a TaqMan-based real-time PCR assay
Chen, S., Chen, Y., Zhang, M., Zhang, W., Fu, H., Huang, Y., Cheng, L., & Wan, C. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1483990 · Cited by 2
Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integrationPreprint
Chen, X., Niu, X., Liu, Y., Zheng, R., Wang, L., Yang, L., Lu, J., Yin, S., Shao, Y., Yu, W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435908 · Cited by 2
Hurnikova, J., Venkatesan, J. K., Liu, W., Madry, H., Cucchiarini, M., & Petrovová, E. (2026) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2026.100404 · Cited by 1
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_150-1 · Cited by 1
Worgall, S., & Crystal, R. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00029-0 · Cited by 3
Mechanisms of AAV neutralization by human alpha-defensins
Porter, J. M., Hulce, K. R., Oswald, M. S., Busuttil, K., Emmanuel, S. N., Bennett, A. D., McKenna, R., & Smith, J. G. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013283 · Cited by 2
“However, poor transduction efficiency and interactions with the host immune system present hurdles that must be overcome to produce more efficient vectors [6,7,9,10].”
Michalakis, S., Gerhardt, M.-J., Priglinger, C., & Priglinger, S. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_150 · Cited by 1
Lundstrom, K. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00049-4 · Cited by 1
Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integrationPreprint
Li, D., Chen, X., Niu, X., Liu, Y., Zheng, R., Wang, L., Yang, L., Lu, J., Yin, S., Shao, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-302699/v1 · Cited by 1
Mechanisms of AAV neutralization by human alpha-defensinsPreprint
Porter, J. M., Hulce, K. R., Oswald, M. S., Busuttil, K., Emmanuel, S. N., Bennett, A. D., McKENNA, R. V., & Smith, J. G. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.25.614754 · Cited by 1
Utilizing CRISPR/Cas9 Technologies for in vivo Disease Modeling and Therapy
Badertscher, L., & Porritt, M. J. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch7
Assaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Alves, E. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-17102023-093636
Perspektivy gennoj terapii gemopoeticheskimi stvolovymi kletkami
Valieva, Y., & POPOV, K. A. (2024) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2024.074
Raboshakga, M. O., Do, A. D., Kurniawati, I., Hsieh, C., & Sung, S. (2025) · Physiology · doi:10.5772/intechopen.1009284 · Cited by 1
In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation
Dong, X., Yan, W., Long, X., & Wu, M. (2026) · BioDrugs · doi:10.1007/s40259-026-00771-3
Matsuyama, S., Guo, C. W., & Diener, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18030395
“To improve efficacy, higher doses of AAVs are needed, but this approach increases toxicity by eliciting greater host immune response [13,14].”
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Gene therapy in Huntington’s disease (HD)
Tirgar, F., Hosseini, M., Alijanpour, S., Aghanoori, M.-R., Alijanpour, S., & Mahdavinataj, H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40467-2.00011-7
Metadata
- Authors
- Rabinowitz, J., Chan, Y. K., & Samulski, R. J.
- Affiliations
- Pfizer (United States) (US)
- Harvard University (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Rabinowitz, Joseph
- Chan, Ying Kai
- Samulski, Richard Jude
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2019-01-25
- Volume
- 11
- Issue
- 2
- Pages
- 102
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC6409805
- OpenAlex
- W2911711918
- Cited by
- 122
- References
- 54
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 17 · 2021: 29 · 2020: 24 · 2019: 6
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (P01HL112761)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, recombinant adeno-associated virus, gene therapy, immune response, AAV serotypes, capsid engineering, antibody epitopes, tissue tropism, blood-brain barrier, ubiquitination, immunomodulation, clinical translation
- MeSH terms
- Host Microbial Interactions, Dependovirus, Animals, Clinical Trials as Topic, Genetic Vectors, Humans, Immunity, Innate, Parvoviridae Infections, Genetic Therapy, Capsid Proteins, Mice, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.